» Articles » PMID: 38482246

A Prognostic Nomogram Integrating Carcinoembryonic Antigen Levels for Predicting Overall Survival in Elderly Patients with Stage II-III Colorectal Cancer

Overview
Date 2024 Mar 14
PMID 38482246
Authors
Affiliations
Soon will be listed here.
Abstract

Background: With the aging of the population, colorectal surgeons will have to face more elderly colorectal cancer (CRC) patients in the future. We aim to analyze independent risk factors affecting overall survival in elderly (age ≥65 years) patients with stage II-III CRC and construct a nomogram to predict patient survival.

Methods: A total of 3,016 elderly CRC patients with stage II-III were obtained from the SEER database. Univariate Cox regression and the least absolute shrinkage and selection operator (LASSO) regression analyses were used to screen independent prognostic factors, and a survival prediction nomogram was constructed based on the results. The consistency index (C-index), decision curve analysis (DCA), Akaike information criterion (AIC), and Bayesian information criterion (BIC) were used to compare the predictive ability between the nomogram and tumor-node-metastasis (TNM) stage system. All patients were classified into high-risk and low-risk groups based on risk scores calculated by nomogram. The Kaplan-Meier method was used to compare the survival differences between two groups.

Results: The 3- and 5-year area under the curve (AUC) values of the prediction nomogram model were 76.6% and 74.8%, respectively. The AIC, BIC, and C-index values of the nomogram model were 6,032.502, 15,728.72, and 0.707, respectively, which were better than the TNM staging system. Kaplan-Meier survival analysis showed a significant survival difference between high-risk and low-risk groups (P<0.0001).

Conclusions: We constructed a prediction nomogram for stage II-III elderly CRC patients by combining pre-treatment carcinoembryonic antigen (CEA) levels, which can accurately predict patient survival. This facilitates clinicians to accurately assess patient prognosis and identify high-risk patients to adopt more aggressive and effective treatment strategies.

Citing Articles

Insights and recommendations for enhancing the prognostic nomogram in elderly patients with stage II-III colorectal cancer.

Dai Y, Feng Q J Gastrointest Oncol. 2024; 15(4):2026-2027.

PMID: 39279947 PMC: 11399859. DOI: 10.21037/jgo-24-322.


Relationships of SIGLEC family-related lncRNAs with clinical prognosis and tumor immune microenvironment in ovarian cancer.

Jin X, Chen Y, Hu Q Sci Rep. 2024; 14(1):7593.

PMID: 38556590 PMC: 10982283. DOI: 10.1038/s41598-024-57946-7.

References
1.
Kim J . Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015; 21(17):5158-66. PMC: 4419056. DOI: 10.3748/wjg.v21.i17.5158. View

2.
Wang H, Li Y, Lei L, Liu C, Chen W, Dai M . Estimating the economic burden of colorectal cancer in China, 2019-2030: A population-level prevalence-based analysis. Cancer Med. 2023; 13(1):e6787. PMC: 10807552. DOI: 10.1002/cam4.6787. View

3.
Hong T, Cai D, Jin L, Zhang Y, Lu T, Hua D . Development and validation of a nomogram to predict survival after curative resection of nonmetastatic colorectal cancer. Cancer Med. 2020; 9(12):4126-4136. PMC: 7300391. DOI: 10.1002/cam4.3010. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Gao Z, Wan Z, Yu P, Shang Y, Zhu G, Jiang H . A recurrence-predictive model based on eight genes and tumor mutational burden/microsatellite instability status in Stage II/III colorectal cancer. Cancer Med. 2023; 13(1):e6720. PMC: 10807589. DOI: 10.1002/cam4.6720. View